King's College Hospital, Department of Urogynaecology, 3rd Floor, Golden Jubilee Wing, London, UK.
Expert Opin Emerg Drugs. 2010 Jun;15(2):299-308. doi: 10.1517/14728211003752702.
Urinary incontinence (UI) is a common problem and there are so many advances done in the field to help treat this common and distressing condition.
In this article we have tried to give an overview about current and emerging drugs available for the management of UI. WHAT THE READERS GAIN: Reading the article will help to fill the knowledge gap regarding drugs available for treatment of UI.
Anti-muscarinic drugs remain the first-line treatment of overactive bladder (OAB) and a favorable efficacy/tolerability:safety ratio can be confirmed, but adverse effects and decreasing compliance remains an issue. Promising new alternatives are emerging but require further controlled studies to confirm their place in treatment of OAB. Surgery is still the mainstay for treatment of stress incontinence although duloxetine is the only drug licensed for this indication.
尿失禁（UI）是一个常见的问题，有这么多的进步在该领域完成，以帮助治疗这种常见的和痛苦的条件。
在这篇文章中，我们试图概述目前和新兴的药物可用于管理的 UI。
阅读这篇文章将有助于填补有关治疗 UI 的可用药物的知识空白。
抗毒蕈碱药物仍然是治疗膀胱过度活动症（OAB）的一线药物，并且可以证实有利的疗效/耐受性：安全性比，但不良反应和降低依从性仍然是一个问题。有前途的新替代品正在出现，但需要进一步的对照研究来确认它们在治疗 OAB 中的地位。手术仍然是治疗压力性尿失禁的主要方法，尽管度洛西汀是唯一为此适应症批准的药物。
